# Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

> **NCT01849848** · PHASE2 · COMPLETED · sponsor: **SymBio Pharmaceuticals** · enrollment: 17 (actual)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **DRUG:** SyB L-0501

## Key facts

- **NCT ID:** NCT01849848
- **Lead sponsor:** SymBio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2015-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01849848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01849848, "Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01849848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*